ATYR PHARMA INC

Wang Lingke’s recent $0.50 buy of ATYR Pharma shares signals insider confidence in the company’s physiocrine platform and strategic growth plans amid market‑access and regulatory hurdles.

SC US (TTGP) buys ATYR Pharma shares, signaling long‑term confidence in its physiocrine biotech platform amid regulatory hurdles and market volatility.

ATYR Pharma’s insider transfer by owner Bothe Roelof reveals a strategic shift in voting power and limited capital‑raising, impacting governance and future funding for its rare‑disorder drug pipeline.

SC US (TTGP)’s 1.2M‑share buy of ATYR Pharma signals strong insider confidence, hinting at future upside amid clinical milestones and market volatility.

ATYR Pharma CEO’s sell‑to‑cover RSU sales: high value, routine tax‑cover moves, hinting at long‑term confidence while short‑term dilution and market chatter spike.

Insider buying surge at ATYR Pharma: Accél Growth Fund’s 11‑Aug purchase signals upcoming milestones, but insider sell‑offs and a negative P/E urge careful timing for investors.

Insider RSU purchases at ATYR signal confidence in its pipeline, hinting at future upside amid current low price and earnings challenges.

Insider selling at ATYR Pharma hits record highs, sparking doubts about its pipeline, pricing strategy, and market position—what this means for investors and future drug development.

Insider buying spree at aTyr Pharma signals confidence ahead of June 2026 IND filing and a Phase 3 trial for efzofitimod—potential upside despite volatility.

CEO Shukla’s insider buying of aTyr Pharma shares signals strong confidence ahead of the 2026 FDA meeting on efzofitimod, hinting at future upside.